Climb Bio flagged initial Phase 1 data for anti-APRIL antibody CLYM116 in healthy volunteers for presentation on Sept. 3, 2026.
Early safety results for CLYM116 were already presented in June, supporting continued development in IgA nephropathy without raising new tolerability concerns.
Dosing is expected to start in Q3 2026 in a Phase 2 IgA nephropathy study run by partner Beijing Mabworks.
Budoprutug programs remain on track, with additional study readouts expected in Q4 2026 across kidney disease, ITP, and SLE.
CLYM•
